HOME >> BIOLOGY >> NEWS
Mouse FH knockout resembles human renal cell cancer

A new mouse model is providing valuable insight into the biochemical pathways that are associated with development of renal cysts and renal cell cancer. The research, published in the April issue of the journal Cancer Cell, published by Cell Press, provides new information about the relationship between hypoxia and cancer progression. In addition, it is likely that this mouse model may prove to be a useful tool for testing therapeutic strategies for renal cell cancer.

Mutations in the Krebs cycle enzyme fumarate hydratase (FH) tumor suppressor gene are present in individuals with renal cysts and renal cell cancer (HLRCC). These mutations are also linked to overexpression of hypoxia-inducible factor (HIF), a transcription factor that is activated when cells are exposed to an environment that is deficient in oxygen. In order to provide a model of HLRCC as well as to further examine the role of Krebs cycle dysfunction in cancer initiation and progression, Dr. Patrick J. Pollard from the Molecular and Population Genetics Laboratory at the London Research Institute and colleagues created a kidney-specific Fh1-deficient mouse model.

The researchers observed that, like humans, the Fh1-deficient mice developed clonal and proliferative renal cysts that exhibited a characteristic overexpression of HIF. The animals eventually succumbed to renal failure. Additional studies went on to show that Fh1 inactivation in mouse embryonic stem cells leads to upregulated HIF. The researchers propose that activation of the hypoxia pathway is likely to be the cause of the cysts in the mice and that if the cysts had not caused renal failure, progression to malignancy may have occurred.

Results from these studies demonstrate that inactivation of FH in the kidney causes activation of the hypoxia pathway and formation of numerous cysts. The researchers conclude that FH deficiency is a direct cause of the increased HIF expression observed in HLRCC tumors and tha
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
9-Apr-2007


Page: 1 2

Related biology news :

1. Mouse model advances understanding of synovial sarcoma
2. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
3. Mouse model underestimates the critical role of Tyk2 in human immune system
4. Mouse DNA to aid biomedical research
5. Mouse strain with gene stutter will help leukemia research
6. Knockout Mouse Project
7. NIH launches Knockout Mouse Project
8. Mouse mimics chronic leukemia, will aid drug development
9. Mouse, frog and bird put Snail and Slug to different uses
10. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
11. Mouse to man: The story of chromosomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
Cached News: